These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23149075)

  • 1. Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.
    Aslibekyan S; An P; Frazier-Wood AC; Kabagambe EK; Irvin MR; Straka RJ; Tiwari HK; Tsai MY; Hopkins PN; Borecki IB; Ordovas JM; Arnett DK
    Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):987-94. PubMed ID: 23149075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suggestion for linkage of chromosome 1p35.2 and 3q28 to plasma adiponectin concentrations in the GOLDN Study.
    Rasmussen-Torvik LJ; Pankow JS; Peacock JM; Borecki IB; Hixson JE; Tsai MY; Kabagambe EK; Arnett DK
    BMC Med Genet; 2009 May; 10():39. PubMed ID: 19426517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.
    Aslibekyan S; Kabagambe EK; Irvin MR; Straka RJ; Borecki IB; Tiwari HK; Tsai MY; Hopkins PN; Shen J; Lai CQ; Ordovas JM; Arnett DK
    Pharmacogenet Genomics; 2012 Mar; 22(3):191-7. PubMed ID: 22228203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.
    Frazier-Wood AC; Aslibekyan S; Borecki IB; Hopkins PN; Lai CQ; Ordovas JM; Straka RJ; Tiwari HK; Arnett DK
    Pharmacogenet Genomics; 2012 Oct; 22(10):750-7. PubMed ID: 22890011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.
    Aslibekyan S; Goodarzi MO; Frazier-Wood AC; Yan X; Irvin MR; Kim E; Tiwari HK; Guo X; Straka RJ; Taylor KD; Tsai MY; Hopkins PN; Korenman SG; Borecki IB; Chen YD; Ordovas JM; Rotter JI; Arnett DK
    PLoS One; 2012; 7(10):e48663. PubMed ID: 23119086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment.
    Christou GA; Tellis KC; Elisaf MC; Tselepis AD; Kiortsis DN
    Hormones (Athens); 2012; 11(2):178-88. PubMed ID: 22801564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.
    Yusuf N; Hidalgo B; Irvin MR; Sha J; Zhi D; Tiwari HK; Absher D; Arnett DK; Aslibekyan SW
    Pharmacogenomics; 2017 Sep; 18(14):1333-1341. PubMed ID: 28835163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
    Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK
    Pharmacogenet Genomics; 2009 Feb; 19(2):161-9. PubMed ID: 19057464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.
    Smith JA; Arnett DK; Kelly RJ; Ordovas JM; Sun YV; Hopkins PN; Hixson JE; Straka RJ; Peacock JM; Kardia SL
    Eur J Hum Genet; 2008 May; 16(5):603-13. PubMed ID: 18212815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.
    Irvin MR; Zhang Q; Kabagambe EK; Perry RT; Straka RJ; Tiwari HK; Borecki IB; Shimmin LC; Stuart C; Zhong Y; Hixson JE; Arnett DK
    Pharmacogenet Genomics; 2012 May; 22(5):367-72. PubMed ID: 22336959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of CDH13 genotypes/haplotypes with circulating adiponectin levels, metabolic syndrome, and related metabolic phenotypes: the role of the suppression effect.
    Teng MS; Hsu LA; Wu S; Sun YC; Juan SH; Ko YL
    PLoS One; 2015; 10(4):e0122664. PubMed ID: 25875811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population.
    Morisaki H; Yamanaka I; Iwai N; Miyamoto Y; Kokubo Y; Okamura T; Okayama A; Morisaki T
    Hum Mutat; 2012 Feb; 33(2):402-10. PubMed ID: 22065538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study.
    Ling H; Waterworth DM; Stirnadel HA; Pollin TI; Barter PJ; Kesäniemi YA; Mahley RW; McPherson R; Waeber G; Bersot TP; Cohen JC; Grundy SM; Mooser VE; Mitchell BD
    Obesity (Silver Spring); 2009 Apr; 17(4):737-44. PubMed ID: 19165155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
    Belfort R; Berria R; Cornell J; Cusi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adiponectin concentrations: a genome-wide association study.
    Jee SH; Sull JW; Lee JE; Shin C; Park J; Kimm H; Cho EY; Shin ES; Yun JE; Park JW; Kim SY; Lee SJ; Jee EJ; Baik I; Kao L; Yoon SK; Jang Y; Beaty TH
    Am J Hum Genet; 2010 Oct; 87(4):545-52. PubMed ID: 20887962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis.
    Galal A; El-Bakly WM; El-Kilany SS; Ali AA; El-Demerdash E
    Behav Pharmacol; 2021 Dec; 32(8):615-629. PubMed ID: 34637209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions.
    Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK
    J Hum Genet; 2008; 53(8):709-717. PubMed ID: 18542840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate.
    Shen J; Arnett DK; Parnell LD; Lai CQ; Straka RJ; Hopkins PN; An P; Feitosa MF; Ordovás JM
    J Cardiovasc Pharmacol; 2012 Mar; 59(3):254-9. PubMed ID: 22075751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Adiponectin and Its Association with Metabolic Traits and Type 2 Diabetes: Gene-Diet Interactions Focusing on Selected Gene Variants and at the Genome-Wide Level in High-Cardiovascular Risk Mediterranean Subjects.
    Coltell O; Ortega-Azorín C; Sorlí JV; Portolés O; Asensio EM; Saiz C; Barragán R; Estruch R; Corella D
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33562295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.